234 related articles for article (PubMed ID: 22429586)
1. Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study.
Papp K; Menter A; Poulin Y; Gu Y; Sasso EH
J Eur Acad Dermatol Venereol; 2013 May; 27(5):634-42. PubMed ID: 22429586
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL.
Gordon K; Papp K; Poulin Y; Gu Y; Rozzo S; Sasso EH
J Am Acad Dermatol; 2012 Feb; 66(2):241-51. PubMed ID: 21752491
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study.
Leonardi C; Sobell JM; Crowley JJ; Mrowietz U; Bao Y; Mulani PM; Gu Y; Okun MM
Br J Dermatol; 2012 Sep; 167(3):658-67. PubMed ID: 22564148
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy.
Papp K; Crowley J; Ortonne JP; Leu J; Okun M; Gupta SR; Gu Y; Langley RG
Br J Dermatol; 2011 Feb; 164(2):434-41. PubMed ID: 21083543
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB
J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of adalimumab when added to inadequate therapy for the treatment of psoriasis: results of PRIDE, an open-label, multicentre, phase IIIb study.
Papp K; Ho V; Teixeira HD; Guerette B; Chen K; Lynde C
J Eur Acad Dermatol Venereol; 2012 Aug; 26(8):1007-13. PubMed ID: 22023702
[TBL] [Abstract][Full Text] [Related]
7. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension.
Reich K; Ortonne JP; Gottlieb AB; Terpstra IJ; Coteur G; Tasset C; Mease P
Br J Dermatol; 2012 Jul; 167(1):180-90. PubMed ID: 22413944
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption.
Gordon KB; Gottlieb AB; Langely RG; van de Kerkhof P; Belasco KT; Sundaram M; Okun M; Serra L
J Eur Acad Dermatol Venereol; 2015 Apr; 29(4):767-76. PubMed ID: 25284275
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.
Menter A; Gordon KB; Leonardi CL; Gu Y; Goldblum OM
J Am Acad Dermatol; 2010 Sep; 63(3):448-56. PubMed ID: 20605254
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
Blauvelt A; Papp KA; Griffiths CE; Randazzo B; Wasfi Y; Shen YK; Li S; Kimball AB
J Am Acad Dermatol; 2017 Mar; 76(3):405-417. PubMed ID: 28057360
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.
Kimball AB; Gordon KB; Fakharzadeh S; Yeilding N; Szapary PO; Schenkel B; Guzzo C; Li S; Papp KA
Br J Dermatol; 2012 Apr; 166(4):861-72. PubMed ID: 22356258
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naïve vs. non-naïve patients.
van Lümig PP; van de Kerkhof PC; Boezeman JB; Driessen RJ; de Jong EM
J Eur Acad Dermatol Venereol; 2013 May; 27(5):593-600. PubMed ID: 22416818
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study.
Kimball AB; Papp KA; Wasfi Y; Chan D; Bissonnette R; Sofen H; Yeilding N; Li S; Szapary P; Gordon KB;
J Eur Acad Dermatol Venereol; 2013 Dec; 27(12):1535-45. PubMed ID: 23279003
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab treatment for severe recalcitrant chronic plaque psoriasis.
Ryan C; Kirby B; Collins P; Rogers S
Clin Exp Dermatol; 2009 Oct; 34(7):784-8. PubMed ID: 19438535
[TBL] [Abstract][Full Text] [Related]
16. Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis.
Gniadecki R; Leonardi CL; Gordon KB; Gu Y; Geng Z; Nader A; Teixeira HD
J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):1297-1304. PubMed ID: 29524255
[TBL] [Abstract][Full Text] [Related]
17. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study.
Thaçi D; Ortonne JP; Chimenti S; Ghislain PD; Arenberger P; Kragballe K; Saurat JH; Khemis A; Sprøgel P; Esslinger HU; Unnebrink K; Kupper H
Br J Dermatol; 2010 Aug; 163(2):402-11. PubMed ID: 20377585
[TBL] [Abstract][Full Text] [Related]
18. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.
Gordon KB; Leonardi CL; Lebwohl M; Blauvelt A; Cameron GS; Braun D; Erickson J; Heffernan M
J Am Acad Dermatol; 2014 Dec; 71(6):1176-82. PubMed ID: 25242558
[TBL] [Abstract][Full Text] [Related]
19. Analysis of body regions and components of PASI scores during adalimumab or methotrexate treatment for patients with moderate-to-severe psoriasis.
Navarini AA; Poulin Y; Menter A; Gu Y; Teixeira HD
J Drugs Dermatol; 2014 May; 13(5):554-62. PubMed ID: 24809878
[TBL] [Abstract][Full Text] [Related]
20. Treatment effect of adalimumab and infliximab in Japanese psoriasis patients: results in a single community-based hospital.
Noda S; Mizuno K; Adachi M
J Dermatol; 2012 Mar; 39(3):265-8. PubMed ID: 22126280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
